Skip to main content

Advertisement

SpringerLink
Log in

Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies

  • Case Report
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Reports of femoral shaft fractures in patients on long-term bisphosphonates (BPs) have raised important concerns on the safety for this class of drugs. Patients with malignancies are potentially at a higher risk for this complication considering the dose and the duration of treatment with BPs. In this report we describe the case of 56-year-old woman with multiple myeloma who developed a non-traumatic left femoral shaft fracture after treatment with high dose BPs for 6 years, following a bone marrow transplant. Intramedullary rod fixation of the fractured femur resulted in “splitting” of the fractured bone followed by poor healing and nonunion of the fractured bone. This case illustrates a potential problem in the management of patients with femoral shaft fractures from prolonged BPs, most especially those who are on high doses for malignant conditions. However, considering the number of patients who benefit from BPs, this complication should not discourage clinicians from using these agents in patients where treatment is indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90(3):1294–1301

    Article  CAS  PubMed  Google Scholar 

  2. Armamento-Villareal R, Napoli N, Panwar V, Novack D (2006) Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355(19):2048–2050

    Article  CAS  PubMed  Google Scholar 

  3. Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93(8):2948–2952

    Article  CAS  PubMed  Google Scholar 

  4. Odvina CV, Levy S, Rao S, Zerwekh JE, Sudhaker RD. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 2009, March 19

  5. Kyle RA, Yee GC, Somerfield MR et al (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25(17):2464–2472

    Article  CAS  PubMed  Google Scholar 

  6. Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735–1744

    Article  CAS  PubMed  Google Scholar 

  7. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090

    Article  CAS  PubMed  Google Scholar 

  8. Cook JR (2008) Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD). Abstract, 2008 ASCO Annual Meeting

  9. Lenart BA, Neviaser AS, Lyman S et al. (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362

    Google Scholar 

  10. Schneider JP (2006) Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 61(1):31–33

    PubMed  Google Scholar 

  11. Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358(12):1304–1306

    Article  CAS  PubMed  Google Scholar 

  12. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39(2):224–231

    Article  PubMed  Google Scholar 

  13. Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89(3):349–353

    Article  PubMed  Google Scholar 

  14. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15(4):613–620

    Article  CAS  PubMed  Google Scholar 

  15. Mashiba T, Turner CH, Hirano T et al (2001) Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 29(3):271–278

    Article  CAS  PubMed  Google Scholar 

  16. Bailey AJ, Paul RG, Knott L (1998) Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 106(1–2):1–56

    Article  CAS  PubMed  Google Scholar 

  17. Gundberg CM, Anderson M, Dickson I, Gallop PM (1986) "Glycated" osteocalcin in human and bovine bone. The effect of age. J Biol Chem 261(31):14557–14561

    CAS  PubMed  Google Scholar 

  18. Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP (2001) Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 28(2):195–201

    Article  CAS  PubMed  Google Scholar 

  19. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D (2009) Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 20(6):887–894

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, MO, USA

    N. Napoli, D. Novack & R. Armamento-Villareal

  2. Division of Endocrinology, Università Campus Bio-Medico, Rome, Italy

    N. Napoli

Authors
  1. N. Napoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Novack
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Armamento-Villareal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Armamento-Villareal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Napoli, N., Novack, D. & Armamento-Villareal, R. Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. Osteoporos Int 21, 705–708 (2010). https://doi.org/10.1007/s00198-009-1012-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-009-1012-0

Keywords

Search

Navigation